Molecular Partners AG (MOLN)
3.60
-0.47
(-11.55%)
USD |
NASDAQ |
May 31, 16:00
Molecular Partners Cash from Operations (TTM): -67.36M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -67.36M |
December 31, 2023 | -65.71M |
September 30, 2023 | -61.93M |
June 30, 2023 | -65.32M |
March 31, 2023 | -70.63M |
Date | Value |
---|---|
December 31, 2022 | 124.32M |
September 30, 2022 | 116.04M |
June 30, 2022 | 114.62M |
March 31, 2022 | 110.60M |
December 31, 2021 | -99.51M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-99.51M
Minimum
Dec 2021
124.32M
Maximum
Dec 2022
3.513M
Average
-63.62M
Median
Cash from Operations (TTM) Benchmarks
AC Immune SA | -47.96M |
CRISPR Therapeutics AG | -159.42M |
Addex Therapeutics Ltd | -8.901M |
NLS Pharmaceutics Ltd | -9.684M |
MoonLake Immunotherapeutics | -48.70M |